Covid-19 Therapy: What Have We Learned In 8 Months?
SARS-CoV-2, a novel pathogenic human coronavirus, emerged in December of 2019 in Wuhan (Hubei province, China). In most cases, the infection causes a mild to moderate respiratory illness. However, a undefined group of infected may develop a severe or critical illness: Coronavirus disease 2019 (COVID...
Main Authors: | Adamczyk-Popławska Monika, Kwiatek Agnieszka |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2020-01-01
|
Series: | Postępy Mikrobiologii |
Subjects: | |
Online Access: | https://doi.org/10.21307/PM-2020.59.3.15 |
Similar Items
-
Sars-Cov-2 And Betacoronavirus: What Have We Learned In 8 Months?
by: Kwiatek Agnieszka, et al.
Published: (2020-01-01) -
SARS-CoV 2 in Cellular Level: Do we dominate the whole picture and how can we intervene?
by: Muhammed Emin, et al.
Published: (2021-03-01) -
Potencial uso terapéutico del ARN de interferencia contra la COVID-19
by: Dany A. Cuello-Almarales, et al.
Published: (2020-06-01) -
Vasculitis and COVID-19: what do we have to know?
by: Antonio Tamburello, et al.
Published: (2020-12-01) -
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
by: Reddy PK, et al.
Published: (2022-05-01)